Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Public ClinicalTrials.gov record NCT00889889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged \>= 18 and \<= 64 years, plus revaccination
Study identification
- NCT ID
- NCT00889889
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1,270 participants
Conditions and interventions
Conditions
Interventions
- Cell-Derived Trivalent Subunit Influenza Vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Jan 2011 (Actual)
- Last update posted
- Oct 25, 2013
2009 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 45690 | Jacksonville | Florida | 32216 | — |
| Site Reference ID/Investigator# 45687 | Pembroke Pines | Florida | 33024 | — |
| Site Reference ID/Investigator# 45697 | South Miami | Florida | 33143 | — |
| Site Reference ID/Investigator# 45691 | Lenexa | Kansas | 66219 | — |
| Site Reference ID/Investigator# 45689 | Overland Park | Kansas | 66212 | — |
| Site Reference ID/Investigator# 45694 | Wichita | Kansas | 67207 | — |
| Site Reference ID/Investigator# 45682 | Lexington | Kentucky | 40509 | — |
| Site Reference ID/Investigator# 45684 | Kansas City | Missouri | 64114 | — |
| Site Reference ID/Investigator# 45685 | Omaha | Nebraska | 68134 | — |
| Site Reference ID/Investigator# 45686 | Las Vegas | Nevada | 89104 | — |
| Site Reference ID/Investigator# 45688 | Raleigh | North Carolina | 27612 | — |
| Site Reference ID/Investigator# 45696 | Nashville | Tennessee | 37203 | — |
| Site Reference ID/Investigator# 45683 | Austin | Texas | 78705 | — |
| Site Reference ID/Investigator# 45695 | Fort Worth | Texas | 76135 | — |
| Site Reference ID/Investigator# 45692 | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00889889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2013 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00889889 live on ClinicalTrials.gov.